SK282717B6 - Spôsob prípravy ultravysokomolekulových hyalurónanov - Google Patents

Spôsob prípravy ultravysokomolekulových hyalurónanov Download PDF

Info

Publication number
SK282717B6
SK282717B6 SK358-2000A SK3582000A SK282717B6 SK 282717 B6 SK282717 B6 SK 282717B6 SK 3582000 A SK3582000 A SK 3582000A SK 282717 B6 SK282717 B6 SK 282717B6
Authority
SK
Slovakia
Prior art keywords
molecular weight
guest
preparation
substituent
derivative
Prior art date
Application number
SK358-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK3582000A3 (en
Inventor
Ladislav �Olt�S
Slavom�R Bystrick�
Bohumil Steiner
Eva Machov�
Raniero Mendichi
Viktor Bauer
Grigorij Kogan
Juraj Alf�Ldi
Eva Stratilov
Mojm�R Mach
Original Assignee
�Stav Experiment�Lnej Farmakol�Gie Sav
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by �Stav Experiment�Lnej Farmakol�Gie Sav filed Critical �Stav Experiment�Lnej Farmakol�Gie Sav
Priority to SK358-2000A priority Critical patent/SK282717B6/sk
Priority to AU2001252180A priority patent/AU2001252180B2/en
Priority to CZ20023029A priority patent/CZ20023029A3/cs
Priority to DE60123225T priority patent/DE60123225T2/de
Priority to ES01925420T priority patent/ES2272465T3/es
Priority to PCT/EP2001/002722 priority patent/WO2001066601A1/en
Priority to JP2001565765A priority patent/JP2003525980A/ja
Priority to US10/220,934 priority patent/US7563824B2/en
Priority to AU5218001A priority patent/AU5218001A/xx
Priority to CA002402421A priority patent/CA2402421C/en
Priority to PL357557A priority patent/PL204330B1/pl
Priority to HU0300163A priority patent/HUP0300163A3/hu
Priority to EP01925420A priority patent/EP1272530B1/en
Priority to NO20024192A priority patent/NO330340B1/no
Publication of SK3582000A3 publication Critical patent/SK3582000A3/sk
Publication of SK282717B6 publication Critical patent/SK282717B6/sk

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK358-2000A 2000-03-10 2000-03-10 Spôsob prípravy ultravysokomolekulových hyalurónanov SK282717B6 (sk)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SK358-2000A SK282717B6 (sk) 2000-03-10 2000-03-10 Spôsob prípravy ultravysokomolekulových hyalurónanov
AU2001252180A AU2001252180B2 (en) 2000-03-10 2001-03-12 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
CZ20023029A CZ20023029A3 (cs) 2000-03-10 2001-03-12 Klatrát a farmaceutický prostředek
DE60123225T DE60123225T2 (de) 2000-03-10 2001-03-12 Clathratekomplexe auf der basis von hyaluronsäurederivaten und deren verwendung als arzneimittel
ES01925420T ES2272465T3 (es) 2000-03-10 2001-03-12 Complejos de clatrato constituidos por derivados del acido hialuronico y su utilizacion como productos farmaceuticos.
PCT/EP2001/002722 WO2001066601A1 (en) 2000-03-10 2001-03-12 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
JP2001565765A JP2003525980A (ja) 2000-03-10 2001-03-12 ヒアルロン酸誘導体により形成されるクラスレート錯体と医薬としてのその用途
US10/220,934 US7563824B2 (en) 2000-03-10 2001-03-12 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
AU5218001A AU5218001A (en) 2000-03-10 2001-03-12 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
CA002402421A CA2402421C (en) 2000-03-10 2001-03-12 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
PL357557A PL204330B1 (pl) 2000-03-10 2001-03-12 Kompleks klatratowy utworzony z pochodnych kwasu hialuronowego, sposób jego otrzymywania, kompozycje farmaceutyczne, ich zastosowania oraz zastosowania pochodnych kwasu hialuronowego
HU0300163A HUP0300163A3 (en) 2000-03-10 2001-03-12 Clathrate complexes formed by hyaluronic acid derivates, process for their preparation and pharmaceutical compositions containing them and their use
EP01925420A EP1272530B1 (en) 2000-03-10 2001-03-12 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
NO20024192A NO330340B1 (no) 2000-03-10 2002-09-03 Klatratkomplekser dannet ved hjelp av hyaluronsyrederivater, medikamenter inneholdende disse, hyaluronsyrederivater, fremgangsmate for fremstilling derav og medikament inneholdende hyaluronsyrederivat samt kontrastmedium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SK358-2000A SK282717B6 (sk) 2000-03-10 2000-03-10 Spôsob prípravy ultravysokomolekulových hyalurónanov

Publications (2)

Publication Number Publication Date
SK3582000A3 SK3582000A3 (en) 2002-09-10
SK282717B6 true SK282717B6 (sk) 2002-11-06

Family

ID=20435814

Family Applications (1)

Application Number Title Priority Date Filing Date
SK358-2000A SK282717B6 (sk) 2000-03-10 2000-03-10 Spôsob prípravy ultravysokomolekulových hyalurónanov

Country Status (13)

Country Link
US (1) US7563824B2 (no)
EP (1) EP1272530B1 (no)
JP (1) JP2003525980A (no)
AU (2) AU5218001A (no)
CA (1) CA2402421C (no)
CZ (1) CZ20023029A3 (no)
DE (1) DE60123225T2 (no)
ES (1) ES2272465T3 (no)
HU (1) HUP0300163A3 (no)
NO (1) NO330340B1 (no)
PL (1) PL204330B1 (no)
SK (1) SK282717B6 (no)
WO (1) WO2001066601A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
JP2004018750A (ja) * 2002-06-18 2004-01-22 Seikagaku Kogyo Co Ltd 親水性を向上したヒアルロン酸誘導体の製造方法
MXPA05002444A (es) 2002-09-06 2005-09-30 Insert Therapeutics Inc Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos.
CA2501132A1 (en) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
WO2004060404A1 (ja) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha 薬物担体
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
EP1884231A1 (en) * 2006-08-01 2008-02-06 Auriga International S.A. Cosmetic or pharmaceutical composition containing hyaluronic acid
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
US8966080B2 (en) * 2007-04-13 2015-02-24 Emc Corporation Systems and methods of managing resource utilization on a threaded computer system
US8658148B2 (en) 2007-06-22 2014-02-25 Genzyme Corporation Chemically modified dendrimers
US8211450B2 (en) 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
JP5890951B2 (ja) 2010-09-13 2016-03-22 ベヴ−アールエックス、インク． 不快味マスキング剤を有する水性薬物送達システム
KR101383941B1 (ko) * 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
AU2014280303A1 (en) * 2013-06-14 2016-02-04 Galderma S.A. Compositions comprising cross-linked hyaluronic acid and cyclodextrin
ITMI20132116A1 (it) 2013-12-18 2015-06-19 Apharm Srl Associazione di glicosamminoglicani e ciclodestrine
CN105153481B (zh) * 2015-10-16 2017-06-16 南开大学 一种荧光超分子纳米粒子及其制备方法和应用
EP3475312B1 (en) 2016-06-23 2020-05-27 Galderma S.A. Cyclodextrin-grafted cross-linked hyaluronic acid complexed with active drug substances and uses thereof
CN106491526B (zh) * 2016-11-14 2019-03-22 暨南大学 一种药物缓释型复合滴眼液及其制备方法与应用
CN106759942B (zh) * 2017-03-01 2022-07-01 邓剑涛 一种一体固化的无焊接销锁连接结构及其施工方法
IT201800007683A1 (it) 2018-07-31 2020-01-31 Altergon Sa Composizioni cooperative sinergiche utili per aumento del tessuto molle, rilascio di farmaco e campi correlati
IT201800009444A1 (it) * 2018-10-15 2020-04-15 Fidia Farm Spa Coniugati tra acido ialuronico e amminobisfosfonati e loro impiego terapeutico
AU2020399792A1 (en) * 2019-12-13 2022-07-21 Folium Labs Inc. Complexes comprising a carbohydrate polymer and an active ingredient and processes for their preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4636524A (en) * 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5470512A (en) * 1990-05-24 1995-11-28 Nippon Kayaku Kabushiki Kaisha Process for producing microcapsules
FR2665158B1 (fr) * 1990-07-30 1993-12-24 Air Liquide Clathrates de peroxyacides.
US5690961A (en) * 1994-12-22 1997-11-25 Hercules Incorporated Acidic polysaccharides crosslinked with polycarboxylic acids and their uses

Also Published As

Publication number Publication date
DE60123225D1 (de) 2006-11-02
PL357557A1 (en) 2004-07-26
ES2272465T3 (es) 2007-05-01
DE60123225T2 (de) 2007-09-20
NO330340B1 (no) 2011-03-28
US20040076680A1 (en) 2004-04-22
AU5218001A (en) 2001-09-17
US7563824B2 (en) 2009-07-21
CA2402421A1 (en) 2001-09-13
HUP0300163A3 (en) 2003-09-29
WO2001066601A1 (en) 2001-09-13
CA2402421C (en) 2009-12-22
PL204330B1 (pl) 2010-01-29
SK3582000A3 (en) 2002-09-10
NO20024192D0 (no) 2002-09-03
EP1272530B1 (en) 2006-09-20
EP1272530A1 (en) 2003-01-08
CZ20023029A3 (cs) 2003-04-16
AU2001252180B2 (en) 2005-06-30
JP2003525980A (ja) 2003-09-02
NO20024192L (no) 2002-09-03
WO2001066601A8 (en) 2002-01-03
HUP0300163A2 (hu) 2003-06-28

Similar Documents

Publication Publication Date Title
SK282717B6 (sk) Spôsob prípravy ultravysokomolekulových hyalurónanov
Weindl et al. Hyaluronic acid in the treatment and prevention of skin diseases: molecular biological, pharmaceutical and clinical aspects
US7651702B2 (en) Crosslinking hyaluronan and chitosanic polymers
Leone et al. Enriched Gellan Gum hydrogel as visco-supplement
US8524213B2 (en) Polymeric materials, their preparation and use
Liao et al. Hyaluronan: pharmaceutical characterization and drug delivery
US8039447B2 (en) Derivatives of hyaluronic acid, their preparation process and their uses
AU2001252180A1 (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
US20040167098A1 (en) Cross-linked polysaccharides
JP2018506603A (ja) エーテル架橋ヒアルロン酸へのアミド結合によるシクロデキストリンのグラフト化およびその使用
CN101501075B (zh) 支化透明质酸和制造方法
Muntimadugu et al. Polysaccharide biomaterials
Wang et al. Acylhydrazone-derived whole pectin-based hydrogel as an injectable drug delivery system
ZA200208299B (en) Polysaccharidic esters of N-derivatives of glutamic acid.
Montanari et al. Halting hyaluronidase activity with hyaluronan-based nanohydrogels: Development of versatile injectable formulations
Wang et al. Polypeptide grafted hyaluronan: synthesis and characterization
Šoltés et al. Molecular characterization of two host–guest associating hyaluronan derivatives
Wang A novel hydrogel crosslinked hyaluronan with glycol chitosan
RU2748261C2 (ru) Композиции, содержащие полисахаридную матрицу для контролируемого высвобождения активных ингредиентов
EP4177276A1 (fr) Composition, sous forme de solution aqueuse comprenant au moins un compose macromoleculaire
Cai Glycosaminoglycans and their binding proteins: Biochemical studies and development of potential wound healing biomaterials
JP2024509534A (ja) ポリマーをベースとする植込み型又は注入型生成物及びそれらの調製方法
Mohamed High-molecular weight of biopolymer
Stern Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett